Novartis’ Phase III Bone Drug Reclast Beats Actonel
This article was originally published in The Pink Sheet Daily
Executive Summary
Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.
You may also be interested in...
Novartis’ Reclast Approved For Fracture Prevention
Expanded labeling for the once-yearly osteoporosis treatment follows the launch of DTC ads.
Novartis’ Reclast Approved For Fracture Prevention
Expanded labeling for the once-yearly osteoporosis treatment follows the launch of DTC ads.
Teva, Barr And Watson Launch Generics Of Merck’s Fosamax
Watson's authorized alendronate generic eases sting of lost exclusivity for the blockbuster osteoporosis drug.